Difficulty: Intermediate | Prerequisites: Basic microbiology (Gram staining, bacterial cell wall structure)
Penicillins are a family of beta-lactam antibiotics that kill bacteria by blocking cell wall synthesis. They were the first antibiotics discovered and remain foundational to pharmacology. Understanding penicillin subclasses, their spectra, and resistance mechanisms is essential before moving on to cephalosporins, carbapenems, and non-beta-lactam agents. You should already be comfortable with Gram staining and basic bacterial cell wall structure.
All penicillins work by inhibiting transpeptidases (penicillin-binding proteins), which cross-link peptidoglycan in the bacterial cell wall, leading to autolysis and cell death. The four subclasses (natural, aminopenicillins, penicillinase-resistant, and beta-lactamase inhibitor combinations) differ mainly in spectrum and stability against bacterial enzymes. Hypersensitivity reactions are a shared adverse effect across every subclass.
Beta-lactam ring
The four-membered ring structure shared by all penicillins, cephalosporins, monobactams, and carbapenems. It is the part of the molecule that binds to and inhibits transpeptidases. Think of it as the "active warhead" of the antibiotic.
Transpeptidase (penicillin-binding protein, PBP)
A bacterial enzyme that cross-links peptidoglycan strands in the cell wall. When a beta-lactam binds to a PBP, cross-linking stops, the wall weakens, and the bacterium lyses. In simple terms, PBPs are the lock, and beta-lactams are the key that jams it.
Peptidoglycan
The mesh-like polymer that gives the bacterial cell wall its structural rigidity. Gram-positive bacteria have a thick peptidoglycan layer; Gram-negative bacteria have a thinner one but add an outer membrane.
Beta-lactamase
A bacterial enzyme that breaks the beta-lactam ring, inactivating the antibiotic. This is the main mechanism of bacterial resistance to penicillins. Think of it as molecular scissors that cut the drug before it can act.
Penicillinase
A type of beta-lactamase produced mainly by staphylococci. It specifically cleaves penicillins but is defeated by penicillinase-resistant agents (nafcillin, oxacillin) or beta-lactamase inhibitors (clavulanate, sulbactam, tazobactam).
Autolysis
The self-destruction of a bacterial cell after its cell wall is weakened by antibiotic inhibition of cross-linking. The cell's own autolytic enzymes break down the compromised wall.
Hypersensitivity reaction
An immune-mediated allergic response to penicillins, ranging from mild rash to life-threatening anaphylaxis. Cross-reactivity exists among penicillin subclasses, with lower cross-reactivity to cephalosporins and carbapenems.
MSSA (methicillin-susceptible Staphylococcus aureus)
Staph strains that remain sensitive to penicillinase-resistant penicillins such as oxacillin and nafcillin.
MRSA (methicillin-resistant Staphylococcus aureus)
Staph strains carrying an altered PBP (PBP2a) that beta-lactams cannot bind to. No standard penicillin covers MRSA; vancomycin is the drug of choice.
Drugs: Penicillin G (IV/IM), Penicillin V (oral form of G)
Key structural feature: Thiazolidine ring fused to a beta-lactam ring.
Pharmacokinetics
Short half-lives, under 2 hours
Penicillin V is the oral formulation; Penicillin G is given parenterally
Spectrum of activity
Good: Streptococcus pyogenes, S. pneumoniae, treponemal infections (syphilis)
Moderate: enterococcal infections
No activity against MRSA, Mycoplasma pneumoniae, or Chlamydophila pneumoniae
Mechanism of action
Inhibit cross-linking of peptidoglycan in the bacterial cell wall by binding PBPs, leading to autolysis and cell death.
Adverse effects
Pharmacologic: minimal at therapeutic doses
Intolerance: GI upset (nausea, vomiting, diarrhoea)
Allergic: hypersensitivity reactions (the class-wide concern)
Clinical pearl: Natural penicillins remain first-line for syphilis and Group A strep pharyngitis where susceptibility is retained.
Drugs: Amoxicillin (oral), Ampicillin (IV)
What makes them different from natural penicillins
Improved Gram-positive coverage over natural penicillin
More water-soluble, so they penetrate Gram-negative outer membranes more readily
Not stable against beta-lactamases (this is their main limitation)
Spectrum of activity
Good: streptococci, enterococci
Moderate: enteric Gram-negative rods (e.g. E. coli), Hemophilus
Poor: staphylococci, anaerobes, Pseudomonas
Mechanism of action
Same as all penicillins: inhibit cross-linking of peptidoglycan via PBP binding, leading to autolysis and cell death.
Adverse effects
GI intolerance (nausea, vomiting, diarrhoea), with a higher incidence of diarrhoea when given orally compared to natural penicillins
Allergic: hypersensitivity reactions
Clinical uses
Amoxicillin: otitis media, sinusitis, acute bacterial cystitis
Ampicillin: IV use for susceptible organisms; alternative UTI treatment for pregnant women
Ampicillin/sulbactam (Unasyn): extends spectrum to many beta-lactamase producers, used for moderate-to-severe intra-abdominal infections, gynecologic infections, and skin/soft-tissue infections
Drugs: Nafcillin, Oxacillin, Dicloxacillin, Methicillin, Cloxacillin
Why they exist
Developed after Staphylococcus became resistant to natural penicillins via penicillinase production. These agents resist hydrolysis by Gram-positive penicillinase.
Spectrum of activity
Good: MSSA, streptococci
Poor: Gram-negative rods, enterococci, anaerobes, MRSA
Mechanism of action
Same beta-lactam MOA: inhibit PBP-mediated cross-linking of peptidoglycan.
Adverse effects
GI intolerance (nausea, vomiting, diarrhoea)
High incidence of allergic interstitial nephritis (AIN), particularly with methicillin, less so with nafcillin and oxacillin
Allergic: hypersensitivity reactions
Key pharmacokinetic points
Oxacillin is stable to beta-lactamase enzymes
Largely eliminated by the liver, so no dose adjustment needed in renal dysfunction
Clinical uses
Endocarditis caused by MSSA
Skin and soft-tissue infections caused by MSSA
Drugs:
Ampicillin/sulbactam (Unasyn)
Amoxicillin/clavulanate (Augmentin), given orally
Piperacillin/tazobactam (Zosyn)
How they work
The beta-lactamase inhibitor (sulbactam, clavulanate, or tazobactam) binds irreversibly to bacterial beta-lactamases, preventing the enzyme from destroying the partner penicillin. The inhibitor does not enhance the penicillin's activity on its own; it simply frees the drug up to reach its PBP target.
Spectrum of activity
Good: MSSA, streptococci, enterococci, many anaerobes, enteric Gram-negative rods
P. aeruginosa: only Zosyn (piperacillin/tazobactam) covers Pseudomonas
Moderate: Gram-negative rods with advanced beta-lactamases
Poor: MRSA, extended-spectrum beta-lactamase (ESBL) producing Gram-negative rods
Adverse effects
GI intolerance (nausea, vomiting, diarrhoea); higher doses correlate with more diarrhoea
Allergic: hypersensitivity reactions
Clinical uses
Good empiric choice for mixed infections: upper and lower respiratory tract infections, UTIs, diabetic ulcers, intra-abdominal infections
Augmentin is a common outpatient empiric antibiotic
Zosyn is a workhorse for broad empiric coverage in hospital settings
Students often think beta-lactamase inhibitors enhance the penicillin's killing power. They do not. They only protect the drug from enzymatic destruction.
Students often assume all penicillins cover MRSA. No penicillin, including the penicillinase-resistant subclass, is effective against MRSA. The "methicillin-resistant" name refers to resistance to the entire antistaphylococcal penicillin class.
Students sometimes confuse aminopenicillins with penicillinase-resistant penicillins. Aminopenicillins (amoxicillin, ampicillin) have broader Gram-negative coverage but are destroyed by beta-lactamases. Penicillinase-resistant agents (oxacillin, nafcillin) resist staphylococcal enzymes but have a narrow spectrum.
A common error is thinking Augmentin covers Pseudomonas. Only piperacillin/tazobactam (Zosyn) among the beta-lactamase inhibitor combinations covers Pseudomonas aeruginosa.
All penicillins share the same MOA (PBP inhibition, peptidoglycan cross-linking disruption, autolysis). If an exam question asks you to identify the mechanism, the answer is always the same across subclasses.
Hypersensitivity is the signature adverse effect across all penicillins. Know that cross-allergenicity exists with cephalosporins (lower risk) and carbapenems (low risk).
Beta-lactams as a class lack activity against Mycoplasma pneumoniae (no cell wall), Chlamydophila pneumoniae, and MRSA.
Zosyn is the only penicillin/inhibitor combination with Pseudomonas coverage. This distinction appears frequently in exam questions about empiric therapy for hospitalised patients.
Methicillin is associated with a high incidence of allergic interstitial nephritis (AIN). This is a commonly tested adverse effect.
Oxacillin and nafcillin are eliminated hepatically, so no renal dose adjustment is needed. Exams test this as a contrast with renally cleared drugs.
True or False: Aminopenicillins are stable against beta-lactamases. (False)
Fill in the blank: The only penicillin/beta-lactamase inhibitor combination with Pseudomonas coverage is ______. (Piperacillin/tazobactam, i.e. Zosyn)
True or False: Penicillinase-resistant penicillins such as nafcillin are effective against MRSA. (False)
Fill in the blank: Beta-lactamase inhibitors work by binding ______ to beta-lactamases. (irreversibly)
True or False: Oxacillin requires dose adjustment in renal failure. (False, it is hepatically cleared)
Q: A patient presents with a skin abscess. Culture grows MSSA. Which penicillin subclass is most appropriate?
A: Penicillinase-resistant penicillins (e.g. nafcillin or oxacillin), as they resist staphylococcal beta-lactamases while retaining activity against MSSA.
Q: Why is amoxicillin ineffective against Pseudomonas aeruginosa?
A: Amoxicillin is an aminopenicillin with poor activity against Pseudomonas. It lacks the structural modifications needed to penetrate the Pseudomonas outer membrane effectively, and it is destroyed by Pseudomonal beta-lactamases.
Q: A patient with a penicillin allergy needs treatment for a Gram-negative rod infection. Which beta-lactam subclass has no cross-reactivity with penicillin?
A: Monobactams (aztreonam). Aztreonam has no cross-allergenicity with penicillins and covers aerobic Gram-negative organisms.
Q: Explain how clavulanate restores amoxicillin's activity against beta-lactamase-producing organisms.
A: Clavulanate binds irreversibly to the bacterial beta-lactamase enzyme, preventing it from breaking amoxicillin's beta-lactam ring. This frees amoxicillin to reach its PBP target and inhibit cell wall synthesis.
Q: A hospitalised patient needs broad empiric coverage including anaerobes and Pseudomonas. Which penicillin combination would you choose?
A: Piperacillin/tazobactam (Zosyn). It is the only penicillin/beta-lactamase inhibitor combination with Pseudomonas coverage and broad anaerobic activity.
This connects directly to cephalosporins, monobactams, and carbapenems, which share the beta-lactam ring and the same fundamental MOA but differ in spectrum and enzyme stability. Understanding penicillin resistance mechanisms (beta-lactamase production, altered PBPs) is the foundation for understanding why later-generation agents were developed.
Vancomycin (glycopeptides) picks up where penicillins leave off: it covers MRSA and other Gram-positive organisms resistant to beta-lactams, and works at an earlier stage of cell wall synthesis (transglycosylation rather than transpeptidation).
Hypersensitivity reactions link to immunology: Type I (anaphylaxis), Type II (haemolytic anaemia), Type III (serum sickness), and Type IV (contact dermatitis) reactions can all occur with penicillins.
Penicillin, penams, beta-lactam antibiotics, cell wall synthesis inhibitors, transpeptidase, PBP, penicillin-binding protein, peptidoglycan cross-linking, autolysis, penicillin G, penicillin V, amoxicillin, ampicillin, aminopenicillin, nafcillin, oxacillin, dicloxacillin, methicillin, cloxacillin, antistaphylococcal penicillin, penicillinase-resistant, beta-lactamase, penicillinase, Augmentin, amoxicillin/clavulanate, clavulanic acid, Unasyn, ampicillin/sulbactam, Zosyn, piperacillin/tazobactam, beta-lactamase inhibitor, MSSA, MRSA, hypersensitivity, anaphylaxis, allergic interstitial nephritis, AIN, empiric therapy, antimicrobial pharmacology, PHAR 101